NEPH stock forecast, quote, news & analysis
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets... Show more
Why Nephros (NEPH) Stock Is Down -15% in the Last 30 Days
Key Takeaways
- Nephros (NEPH) shares declined roughly 15% over the last 30 days, falling from $3.29 on October 8, 2026, to $2.79 at the close on November 6, 2026.
- The pullback extends a broader slide of about 34% over the trailing three months, from an early-August level near $4.20.
- Third-quarter results released November 5 showed 18% year-over-year revenue growth and an earnings beat, yet margin pressure from tariffs, shipping costs, and revenue mix weighed on sentiment.
- Gross margin narrowed to about 58% in Q3 2026 from 61% a year earlier, reflecting higher tariff and shipping expenses plus faster growth in lower-margin service revenue.
- As a thinly traded micro-cap with a five-year beta near 1.75, NEPH tends to experience outsized price swings on relatively modest trading volume.
- Explore Nephros' Price Targets, Earnings, and Forecast pages for additional detail on valuation, fundamentals, and forward estimates.
- Interested in data-driven trading ideas? Explore Trending AI Robots to see curated, top-performing AI trading bots.
Nephros (NEPH) Company Overview and Market Position
Nephros, Inc. is a water technology company that develops and sells high-performance, point-of-use filtration solutions for medical and commercial markets. In healthcare, its FDA-cleared ultrafilters are used in hospitals to help prevent infection from waterborne pathogens such as legionella and pseudomonas, and in dialysis centers to remove biological contaminants from water and bicarbonate concentrate. In commercial markets, the company supplies filters that improve taste and odor and reduce biofilm, lead, and scale build-up, serving foodservice, hospitality, convenience-store, and industrial customers.
Founded in 1997 and headquartered in South Orange, New Jersey, Nephros operates a small but profitable business: trailing twelve-month revenue of roughly $20.7 million with positive net income. Investors follow the stock for its recurring "programmatic" revenue model, its expanding active customer base, and its push into service and education offerings under a "products, service, education" strategy.
Nephros (NEPH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NEPH declined from $3.29 (October 8 close) to $2.79 (November 6 close), a drop of about 15%. The move was uneven: shares briefly traded above $3.60 in mid-October before selling off sharply in late October and again in the session following third-quarter earnings.
The recent decline is part of a longer downtrend. From an early-August close near $4.20, the stock has fallen roughly 34% through early November, and it now trades near the low end of its 52-week range of $2.66 to $6.42. After peaking around $4.70 to $4.87 in mid-August, the shares trended lower through September and October despite generally improving operating results.
What Drove NEPH Stock Price in the Last 30 Days
The most significant scheduled event was the release of third-quarter 2026 results on November 5. Nephros reported net revenue of approximately $5.62 million, up 18% year over year, with net income of about $0.5 million and adjusted EBITDA of roughly $0.6 million. Earnings of $0.05 per share exceeded consensus expectations, yet the stock fell 9.71% the following session.
A key driver of investor caution was margin compression. Gross margin declined to approximately 58% in Q3 2026 from 61% in the prior-year period, which management attributed to higher inventory, shipping, and handling costs—including tariff expense—as well as faster growth in service revenue, which carries a lower margin than product sales. The company also cited foreign currency movements and tariffs among ongoing cost pressures.
Beyond fundamentals, NEPH's price action reflects its profile as a low-float micro-cap. With average daily volume near 39,000 shares and a beta near 1.75, relatively modest selling can produce large percentage moves, as seen in several elevated-volume sessions during the period.
What Drove NEPH Stock Performance Over the Last Quarter
Over the trailing three months, NEPH has given back most of the gains that carried it to its summer highs. After a strong first half, the shares peaked in August and have since re-rated lower even as the underlying business continued to grow. For the first nine months of 2026, revenue rose 20% to approximately $16.85 million and net income increased to about $1.85 million.
The broader decline reflects a combination of persistent margin headwinds, tariff-policy uncertainty, and a generally cautious backdrop for small-cap names. Nephros also carries company-specific risks: three customers accounted for about 44% of 2025 revenue, and the company relies on a single exclusive supplier for key filtration materials. These factors, together with limited trading liquidity, have contributed to the stock's extended slide from its mid-August levels.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in its curated Trending AI Robots section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a range of approaches—from short-term technical signals to longer-horizon models. The section is designed to surface the bots currently demonstrating the strongest and most consistent results, making it easier for investors to evaluate data-driven trading ideas without manually sifting through the full catalog. Browsing the page can offer a useful starting point for those looking to complement their own research with systematic, AI-generated signals.
NEPH Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on several factors. First, the company's fourth-quarter and full-year 2026 results will provide the next read on whether revenue growth and profitability momentum can continue, and whether gross margins stabilize or face further pressure from tariffs, shipping costs, and product mix. Second, progress on expanding the active customer base—which reached a record 1,766 sites in Q3—and on service-revenue growth will be closely watched.
Additional items to monitor include the company's reliance on a single supplier, remediation of a previously disclosed internal-control weakness related to revenue recognition, and customer concentration. Analyst sentiment remains constructive, with a reported average price target near $6.25 versus the current share price, but small-cap liquidity, tariff policy, and broader market risk appetite will likely continue to influence near-term volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NEPH sees its Stochastic Oscillator ascends from oversold territory
On November 10, 2026, the Stochastic Oscillator for NEPH moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 63 instances where the indicator left the oversold zone. In 51 of the 63 cases the stock moved higher in the following days. This puts the odds of a move higher at over 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NEPH's RSI Indicator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +12.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where NEPH advanced for three days, in 165 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NEPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NEPH as a result. In 81 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NEPH turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 30 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for NEPH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 53 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.532) is normal, around the industry mean (4.964). P/E Ratio (17.438) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.318) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. NEPH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system
Industry PharmaceuticalsOther